Quanterix Q1 revenue $32.1M (+12.7%); net loss $10.1M; FDA breakthrough for P-tau217 test

Quanterix Corp

2024-Q1 EPS reported -$0.26 revenue$32,066,000

Revenue $32.1M (+12.7% YoY); net loss $10.1M (increase of $4.0M YoY).
GAAP gross margin 61.2% (up 170 bps); non-GAAP gross margin 54.5% (up 140 bps).
FY 2024 guidance unchanged: revenue $139-$144M, GAAP gross margin 57-61%, non-GAAP 51-55%.
Director Brian J. Blaser resigned board eff. May 3, 2024 to become CEO of QuidelOrtho; no disagreement.
Simoa P-tau217 blood test granted FDA Breakthrough Device; Lilly launched CertuitAD test on SP-X platform.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian J. Blaser

Director

QTRX · Quanterix Corp

Effective: 2024-05-03
Filed: May 7, 2024, 7:59 PM ET

On May 2, 2024, Brian J. Blaser notified Quanterix of his resignation from its Board of Directors, effective as of May 3, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Quanterix Corp reported first quarter ended March 31, 2024 results: revenue $32.1 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $32.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

to study and enable the early detection of neuro-pathologies such as Multiple Sclerosis, Parkinson’s, and Alzheimer’s disease.” First Quarter Financial Highlights ● Revenue of $32.1 million, an increase of 12.7% compared to $28.5 million in the prior year period. ● GAAP gross margin of 61.2%, an increase of approximately 170 basis points compared to the prior year

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian J. Blaser resigned as Director at Quanterix Corp.

Action: resigned
Role: Director

Exact text from the filing

On May 2, 2024, Brian J. Blaser notified Quanterix of his resignation from its Board of Directors, effective as of May 3, 2024.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-007059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.